The GBA-PD Consortium is an international collaborative network dedicated to understanding and treating Parkinson's disease in individuals carrying mutations in the GBA1 (glucocerebrosidase) gene. Heterozygous GBA1 mutations are among the most significant genetic risk factors for Parkinson's disease, increasing risk by 5-6 fold in carriers.
- GBA1 Gene: Encodes glucocerebrosidase, an enzyme that breaks down glucosylceramide
- Mutation Types: Includes N370S, L444P, RecNciI, and other variants
- Carrier Frequency: 5-10% of PD patients carry GBA1 mutations
- Lysosomal dysfunction leading to alpha-synuclein accumulation
- Impaired autophagy and mitochondrial dysfunction
- Endoplasmic reticulum stress
- Neuroinflammation pathways
GBA-PD typically presents with:
- Earlier age of onset (mean ~55 years vs ~65 years for idiopathic PD)
- Higher prevalence of non-motor symptoms
- More rapid progression in some carriers
- Increased risk of cognitive decline and dementia
- Clinical Characterization: Standardizing assessment of GBA-PD phenotype
- Genetics & Biomarkers: Developing GBA-specific biomarkers
- Therapeutic Development: Targeting GBA-related pathways
- Clinical Trials: Planning trials for GBA-PD specific therapies
| Trial |
Drug |
Phase |
Status |
NCT |
| GBA-PD Natural History |
- |
Observational |
Recruiting |
NCT04116437 |
| Ambroxol Trial |
Ambroxol |
Phase 2 |
Recruiting |
NCT02914366 |
| LTI-03 |
LTI-03 (GCase stabilizer) |
Phase 1 |
Recruiting |
NCT04831016 |
- Enzyme Enhancement: Ambroxol, LTI-03 (GCase activators)
- Substrate Reduction: GZ161 (glucosylceramide synthase inhibitor)
- Gene Therapy: AAV-based GBA1 delivery
The GBA1 gene encodes glucocerebrosidase (GCase), a lysosomal enzyme that catalyzes the hydrolysis of glucosylceramide to ceramide and glucose[@johannsen1999]. GBA1 mutations lead to reduced enzyme activity, causing:
- Glucosylceramide accumulation: Substrate accumulation in lysosomes
- Autophagy impairment: Defective autophagosome-lysosome fusion[@sun2020]
- Alpha-synuclein aggregation: Direct link to PD pathology[@cullen2011][@mazzulli2011]
flowchart TD
A["GBA1 Mutation"] --> B["Reduced GCase Activity"]
B --> C["Glucosylceramide Accumulation"]
C --> D["Lysosomal Dysfunction"]
D --> E["Autophagy Impairment"]
E --> F["Alpha-Synuclein Accumulation"]
F --> G["Lewy Body Formation"]
C --> H["Mitochondrial Dysfunction"]
C --> I["ER Stress"]
H --> G
I --> G
- Mitochondrial dysfunction: GCase deficiency affects mitochondrial quality control
- Endoplasmic reticulum stress: Misfolded GCase triggers UPR
- Neuroinflammation: Glucosylceramide activates microglia
- Synaptic dysfunction: Loss of GCase affects synaptic homeostasis
GBA-PD patients exhibit distinct clinical features compared to idiopathic PD[@beces2021][@mallett2022]:
| Feature |
GBA-PD |
Idiopathic PD |
| Mean age of onset |
~55 years |
~65 years |
| Cognitive impairment |
60-80% at 5 years |
30-40% at 5 years |
| Non-motor symptoms |
More severe |
Less severe |
| Progression rate |
Faster in some |
Variable |
| Levodopa response |
Generally good |
Generally good |
GBA-PD patients show higher prevalence of:
- Cognitive decline/dementia: Earlier and more severe[@thaler2018]
- REM sleep behavior disorder: Very common
- Autonomic dysfunction: Orthostatic hypotension
- Olfactory impairment: Often severe
- Psychiatric symptoms: Depression, anxiety
Certain GBA1 variants are associated with rapid progression[@varga2021]:
- Severe mutations: L444P, RecNciI, D409H
- Complex homozygous/compound heterozygous: More severe phenotype
- Earlier onset: Predicts faster progression
-
Clinical Characterization: Standardizing assessment of GBA-PD phenotype
- Unified assessment battery
- Cognitive testing protocols
- Biomarker collection standards
-
Genetics & Biomarkers: Developing GBA-specific biomarkers
- Blood-based biomarkers
- CSF biomarkers
- Imaging markers
-
Therapeutic Development: Targeting GBA-related pathways
- GCase modulators
- Substrate reduction therapy
- Gene therapy approaches
-
Clinical Trials: Planning trials for GBA-PD specific therapies
- Trial design for genetic subgroups
- Endpoint selection
- Patient stratification
| Mutation |
Population |
Frequency in PD |
Severity |
| N370S |
Ashkenazi Jewish |
15-20% |
Mild |
| L444P |
Various |
5-10% |
Severe |
| RecNciI |
Various |
3-5% |
Severe |
| E326K |
European |
3-5% |
Mild |
| T369M |
Various |
2-3% |
Mild |
- Severe: L444P, RecNciI, D409H, 84GG, IVS2+1
- Mild: N370S, E326K, T369M
- Risk modifiers: L179P, R496H
GBA1 variant frequencies vary by ancestry[@liuj2015][@brautbar2012]:
- Ashkenazi Jews: 15-20% carrier rate
- European: 3-5% carrier rate
- Asian: <1% carrier rate
- Mechanism: Molecular chaperone that increases GCase activity
- Evidence: Increases GCase activity in humans[@oricht2020]
- Status: Phase 2 trial ongoing (NCT02914366)
- Dose: 1260 mg/day (split dosing)
- Mechanism: Small molecule GCase stabilizer
- Evidence: Preclinical promise
- Status: Phase 1 complete (NCT04831016)
- Mechanism: Glucosylceramide synthase inhibitor
- Goal: Reduce substrate accumulation
- Status: Preclinical/early clinical
- Mechanism: Deliver functional GBA1 gene
- Challenges: Target neurons, avoid immune response
- Status: Preclinical development
- Small molecule chaperones: Pyrazolopyridine derivatives
- Protein replacement: Recombinant GCase (not crossing BBB)
- Cell-based therapy: Stem cell-derived neurons
- GBA1 mutation status
- Carrier vs. affected vs. non-carrier
- Variant-specific risk stratification
- Glucosylceramide: Elevated in GBA-PD
- Glucosylsphingosine: More specific marker
- GCase activity: Reduced in carriers
- Alpha-synuclein: Seed amplification assay
- Dopamine transporter imaging (DAT)
- MR volumetry (hippocampal atrophy)
- PET for synaptic density
- Clinical rating scales (MDS-UPDRS)
- Cognitive assessments (MoCA, CDR)
- Motor fluctuations
- Non-motor symptom scales
Centralized database including:
- Clinical data from 50+ centers
- Genetic information
- Biomarker samples
- Longitudinal follow-up
- DNA samples
- CSF samples
- Serum samples
- Post-mortem brain tissue (limited)
- Standardized data dictionary
- Open access for approved researchers
- Collaborative analysis projects
- International GBA-PD Registry
- Standardized clinical assessment protocols
- Shared biobank of patient samples
- Collaborates with Cure Parkinson's Linked Clinical Trials
- Partners with pharmaceutical companies on clinical trials
- Engages with patient advocacy groups
- Complete Ambroxol Phase 2 trial
- Validate blood-based biomarkers
- Establish genotype-phenotype correlations
- Advance gene therapy to clinical trials
- Develop combination therapies
- Achieve disease modification in GBA-PD
| Year |
Finding |
Reference |
| 2009 |
First large multicenter GBA-PD study[@sidransky2009] |
PMID: 19846850 |
| 2011 |
GBA and alpha-synuclein mechanism[@mazzulli2011] |
PMID: 21840945 |
| 2015 |
Longitudinal progression in GBA-PD[@Alcalay2015] |
PMID: 26500304 |
| 2019 |
Comprehensive review[@sidransky2019] |
PMID: 31010158 |
| 2020 |
Ambroxol trial results[@oricht2020] |
PMID: 32150231 |
| 2021 |
Phenotype characterization[@beces2021] |
PMID: 34152489 |
| 2022 |
Natural history study[@mallett2022] |
PMID: 35532210 |
- Mitsui J, et al, GBA Variants and Parkinson Disease: Mechanisms and Treatments (2022)
- Sidransky E, et al, GBA, Gaucher Disease, and Parkinson's Disease (2019)
- Sidransky E, et al, Multicenter analysis of glucocerebrosidase mutations in PD (2009)
- Sidransky E et al, GBA mutations in Parkinson disease (2020)
- Schapira AH et al, Glucocerebrosidase and Parkinson disease (2019)
- Alcalay RN et al, GBA and alpha-synuclein (2020)
- Beces E et al, GBA variants in PD: phenotype and progression (2021)
- Mallett L et al, GBA-PD natural history study (2022)
- Thaler A et al, GBA mutations and cognitive decline in PD (2018)
- Varga N et al, GBA1 variants and rapid progression in PD (2021)
- Johannsen P et al, Glucocerebrosidase activity in PD (1999)
- Goker-Alpan O et al, GBA and synucleinopathies (2020)
- Sun Y et al, GBA1 in lysosomal function (2020)
- Cullen V et al, GBA and alpha-synuclein toxicity (2011)
- Mazzulli JR et al, GBA loss leads to alpha-synuclein accumulation (2011)
- Oricht M et al, Ambroxol increases GCase activity in GBA-PD (2020)
- Silva BA et al, GCase activators for PD (2022)
- Cherni L et al, GBA gene therapy approaches (2020)
- Poston KL et al, GBA-PD clinical trials update (2022)
- Alcalay RN et al, Longitudinal analysis in GBA-PD (2015)
- Liu G et al, GBA variant frequency in diverse populations (2015)
- Brautbar A et al, GBA carrier frequency in Ashkenazi Jews (2012)